CLDN18.2 Reporting Template

**CLDN18.2 Reporting Status by IHC**

Developed collaboratively by the CLDN18.2 Expert Committee, the following template can help you generate and integrate CLDN18.2 reporting into your current protocols.

**Scoring algorithm**

Percentage of tumour cells demonstrating moderate-to-strong (2+/3+) membranous CLDN18-specific staining.

**Percentage of tumour cells with membranous staining**

Tumour cells with moderate staining (2+): \_\_\_\_\_\_\_\_\_\_\_\_

Tumour cells with strong staining (3+): \_\_\_\_\_\_\_\_\_\_\_\_

Total tumour cells with moderate-to-strong (2+/3+) staining: \_\_\_\_\_\_\_\_\_\_\_\_ *(Sum of 2 lines above)*

**CLDN18.2 status**

*(Select one)*

\_\_\_\_ Inconclusive

\_\_\_\_ Positive (≥75% tumour staining)

\_\_\_\_ Negative (<75% tumour staining)

**CLDN18.2 testing method** (Protein expression by immunohistochemistry)

*(Select one)*

\_\_\_\_ US Food and Drug Administration (FDA) cleared: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ *(Specify test/vendor)*

\_\_\_\_ Laboratory-developed test: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ *(Specify test/vendor)*

**Notes**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

The CLDN18.2 Expert Committee is comprised of some of the world’s leading pathologists, including Matteo Fassan, MD, PhD, Takeshi Kuwata, MD, PhD, Kristina A. Matkowskyj, MD, PhD, Christoph Röcken, MD, and Josef H. Rüschoff, MD. The members of the committee have been contracted as paid advisors through Astellas Pharma Inc. and have received compensation for their time.

IHC = Immunohistochemistry

©2024 Astellas Pharma Inc. MAT-ABC-ZOL-2023-00284 02/24 NOT FOR PROMOTION.